Connect with us
Good Addiction
Does the cloud of unpleasant symptoms associated with discontinuation of drugs like venlafaxine and paroxetine have a silver lining? Maybe it helps adherence.
We rarely worry that methadone or buprenorphine maintenance patients will skip doses or stop altogether. Not so fluoxetine which tapers itself so slowly that patients can stop with little fear of abstinence symptoms.
Should pharma strive to make more drugs addictive in order to assure adherence to critical treatment?